Dynavax Technologies Corp [DVAX] stock prices are down -0.62% to $9.69 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DVAX shares have gain 2.98% over the last week, with a monthly amount drifted -7.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dynavax Technologies Corp [NASDAQ: DVAX] stock has seen the most recent analyst activity on February 11, 2025, when Goldman downgraded its rating to a Sell and also revised its price target to $12 from $15. Previously, Goldman started tracking the stock with Neutral rating on February 01, 2024, and set its price target to $20. On September 27, 2022, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $22 on the stock. Goldman initiated its recommendation with a Buy and recommended $19 as its price target on August 06, 2021. H.C. Wainwright reiterated a Buy rating for this stock on August 07, 2020, and downed its price target to $12. In a note dated August 03, 2020, H.C. Wainwright reiterated a Buy rating on this stock and boosted its target price from $12 to $14.
The stock price of Dynavax Technologies Corp [DVAX] has been fluctuating between $9.20 and $14.63 over the past year. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Dynavax Technologies Corp [NASDAQ: DVAX] shares were valued at $9.69 at the most recent close of the market. An investor can expect a potential return of 230.24% based on the average DVAX price forecast.
Analyzing the DVAX fundamentals
The Dynavax Technologies Corp [NASDAQ:DVAX] reported sales of 316.27M for trailing twelve months, representing a surge of 29.33%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.09 and Total Capital is -0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Dynavax Technologies Corp [NASDAQ:DVAX]’s Current Ratio is 6.65. Further, the Quick Ratio stands at 6.01, while the Cash Ratio is 0.84. Considering the valuation of this stock, the price to sales ratio is 3.59, the price to book ratio is 2.30.
Transactions by insiders
Recent insider trading involved Myers Scott Dunseth, Director, that happened on Aug 22 ’25 when 3800.0 shares were purchased. 10% Owner, Deep Track Biotechnology Maste completed a deal on Aug 21 ’25 to sell 1.09 million shares. Meanwhile, 10% Owner Deep Track Biotechnology Maste sold 0.97 million shares on Aug 22 ’25.
